Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors (Q33921891)

24711126

30 July 2017

title

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors (English)

1 reference

30 July 2017

1 reference

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Fatima Rangwala

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Johanna C Bendell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Mark F Kozloff

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Christy C Arrowood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Andrew Dellinger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Jennifer Meadows

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sandra Tourt-Uhlig

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Jennifer Murphy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Kellen L Meadows

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Aijing Starr

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Samuel Broderick

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

John C Brady

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Stephanie M Cushman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Michael A Morse

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Hope E Uronis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

S David Hsu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

James Wallace

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Alexander N Starodub

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Andrew B Nixon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Herbert I Hurwitz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

9 April 2014

1 reference

24711126

Investigational New Drugs

30 July 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

700-709

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)

13 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Interleukin-6 as a therapeutic target in human ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Roles for the type III TGF-beta receptor in human cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Serum interleukin-6 levels in colorectal cancer patients--a summary of published results

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Targeting the mTOR signaling network for cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Modes of resistance to anti-angiogenic therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

The type III TGF-beta receptor suppresses breast cancer progression

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

5 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0089-2

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0089-2

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0089-2

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0089-2

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0089-2

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0089-2

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0089-2

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4103954

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24711126

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-014-0089-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

24711126

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24711126%20AND%20SRC:MED&resulttype=core&format=json